NTT-DOCOMO/NEC
26.2.2024 09:06:25 CET | Business Wire | Press release
NTT DOCOMO, INC. and NEC Corporation announced today that they plan to establish a joint venture company, OREX SAI, INC. on April 1 to provide OREX Packages solutions for the full-scale global deployment of Open RAN services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226531069/en/
Overview of OREX SAI (Graphic: Business Wire)
OREX SAI will locally source products and services from members of OREX PARTNERS in each market and perform system verifications to deliver mobile networks tailored to the needs of each overseas telecommunications operator. Leveraging NEC’s established business infrastructure and global network in over 50 countries and territories, the joint venture will accelerate its global expansion of Open RAN business.
In addition, DOCOMO and NEC plan to strengthen cooperation with OREX PARTNERS through OREX SAI to promote the commercialization and realization of true Open RAN that enables the interoperability of equipment and systems from diverse vendors.
The joint venture will procure all necessary Open RAN network equipment and software from OREX PARTNERS, and then conduct system verification for the planning and construction of optimal mobile networks tailored to each telecom operator. Full-stack services will include planning, construction, maintenance and operation under the OREX Packages framework.
DOCOMO established the O-RAN ALLIANCE with leading global telecom operators in February 2018 and launched the world’s first nationwide Open RAN 5G service in Japan in March 2020. Since introducing the OREX® brand in February 2023, DOCOMO has been supporting Open RAN verifications for global telecom operators to help realize more open mobile networks around the world.
NEC, having delivered Open RAN solutions to telecom operators in Japan and other countries, was selected by DOCOMO as a vendor for virtualized radio access networks (vRANs), one of DOCOMO’s 5G commercial services in Japan. With extensive experience in building communication infrastructure around the world, NEC offers strong system-integration (SI) capabilities.
In their collaboration with OREX PARTNERS to realize Open RAN, DOCOMO and NEC recognize the importance of optimizing local product and service delivery. In response, they will now form a joint venture company to establish a global system capable of accelerating the realization of Open RAN.
Hiroshi Kobayashi, President and CEO of OREX SAI, said, “We are excited to bring our true Open RAN solutions to telecom operators worldwide through the joint venture OREX SAI, which combines DOCOMO’s Open RAN implementation expertise, OREX’s innovative solutions and NEC’s global system-integration capabilities. We are committed to driving innovation and connectivity for all, making global telecommunications open, seamless and inclusive.”
Going forward, OREX SAI will work with OREX PARTNERS to provide optimal products and services that accelerate the global adoption of high-quality, cost-effective and energy-efficient Open RAN solutions. In addition, they will enhance cooperation with global partners to foster a vibrant and open ecosystem.
The new company will also explore application of the NTT’s IOWN all-photonic network for transmission, the use of low-power servers equipped with optoelectronic devices, and collaboration with the Cognitive Foundation®.
Joint Venture Overview |
|
Official Name |
OREX SAI, INC. |
Headquarters |
59-16 Nisshin-cho, Kawasaki-ku, Kawasaki City, Kanagawa, Japan 210-0024 |
President and CEO |
Hiroshi Kobayashi |
Business |
|
Total Assets |
JPY 16 billion (including capital reserve) |
Establishment |
April 1, 2024 (tentative) |
Shareholders |
DOCOMO 66% and NEC 34% |
OREX is a trademark of NTT DOCOMO, INC.
For more detailed information, please refer to the full press release available at www.docomo.ne.jp/english/info/media_center/pr/
About NTT DOCOMO
NTT DOCOMO, Japan’s leading mobile operator with over 89 million subscriptions, is one of the world’s foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226531069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom